Background: One of the common clinical manifestations in patients with chronic liver disease
is the symptom of pruritus which has been reported in about ۸۰ to ۱۰۰ %. In a subset of patients, nearly ۱۰ to ۲۰ %, the symptom becomes refractory and can lead to depression, inability to sleep, and even suicidal attempts. Aim of the study: The aim of the current study was to evaluate efficacy and safety of sertraline in treatment of pruritus associating chronic liver disease, diabetes mellitus, and atopic dermatitis.Patients and methods: Sertraline
was given at dose (۷۵-۱۰۰ mg/day) to all enrolled patients for ۱۲ weeks. During this period patients were followed up for side effects.Results: The highest rate was seen in chronic liver disease, patients followed by diabetes mellitus, and then by atopic dermatitis. Comparison of rate of satisfactory response among the study groups revealed no significant difference between chronic liver disease
group and diabetes mellitus group (p = ۰.۶۴۳). Whereas, the rate was significantly higher in patients with chronic liver disease
in comparison with control group (p = ۰.۰۳۳). Conclusion: Sertraline
is an efficient and safe pharmacological agent for relief of pruritus not only in patients with chronic liver disease, in whom it has the best rate of satisfactory response, but also in other disorders such as diabetes mellitus and to a lesser extent atopic dermatitis.